Physician profile
Deva Sharma
NPI 1255620845
$9,350.05
in general payments reported to CMS, 2019-2025
5 companies · $2,573 in 2025
The $2,573 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.00 · 2021: $1,900 · 2023: $4,083 · 2024: $700 · 2025: $2,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,083 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,000 · Honoraria: $1,700 · Gift: $1,485 · Food and Beverage: $87.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,082.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,000.00 |
| Honoraria | $1,700.00 |
| Gift | $1,485.00 |
| Food and Beverage | $87.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Bct, INC. | $3,900.00 | 2021-2023 | Spectra Optia |
| Cerus Corporation | $3,185.00 | 2024-2025 | Intercept Blood System For Platelets |
| Novo Nordisk INC | $2,082.50 | 2023 | |
| Astellas Pharma US INC | $95.00 | 2019 | |
| Genetix Biotherapeutics INC | $87.55 | 2025 | Lyfgenia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deva Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.